{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:54:54Z","timestamp":1780610094567,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jaut.2020.102454","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T17:08:31Z","timestamp":1586884111000},"page":"102454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database"],"prefix":"10.1016","volume":"111","author":[{"given":"C\u00e9line","family":"Anquetil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Touhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Desbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Maalouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Domont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2020.102454_bib1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjo.80.9.844","article-title":"The possible impact of uveitis in blindness: a literature survey","volume":"80","author":"Suttorp-Schulten","year":"1996","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jaut.2020.102454_bib2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.ophtha.2014.07.007","article-title":"Long-term clinical outcome and causes of vision loss in patients with uveitis","volume":"121","author":"Tomkins-Netzer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaut.2020.102454_bib3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaophthalmol.2013.4237","article-title":"Incidence and prevalence of uveitis: results from the pacific ocular inflammation study","volume":"131","author":"Acharya","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaut.2020.102454_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in northern California; the northern California epidemiology of uveitis study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaut.2020.102454_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09273948.2016.1196713","article-title":"A focus on the epidemiology of uveitis","volume":"26","author":"Tsirouki","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.jaut.2020.102454_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of noninfectious uveitis in the United States: a claims-based analysis","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaut.2020.102454_bib7","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/09273948.2016.1249376","article-title":"Ocular autoimmune systemic inflammatory infectious study (OASIS) - report 1: epidemiology and classification","volume":"26","author":"Chen","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.jaut.2020.102454_bib8","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/bjo.83.10.1153","article-title":"Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis","volume":"83","author":"Ambati","year":"1999","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jaut.2020.102454_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199403243301218","volume":"330","author":"Frank","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102454_bib10","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jamaophthalmol.2014.3024","article-title":"Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib","volume":"132","author":"Guedj","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaut.2020.102454_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","article-title":"Checkpoint inhibitor-induced uveitis: a case series","volume":"256","author":"Conrady","year":"2018","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jaut.2020.102454_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102454_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ICB.0000000000000368","article-title":"Pembrolizumab administration associated with posterior uveitis","volume":"11","author":"Aaberg","year":"2017","journal-title":"Retin. Cases Brief Rep."},{"key":"10.1016\/j.jaut.2020.102454_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and clinical patterns of ocular complications associated with anti-PD-1\/PD-L1 anticancer immunotherapy","volume":"202","author":"Bitton","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.jaut.2020.102454_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.jaut.2020.102454_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2020.102454_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.jaut.2020.102454_bib18","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102454_bib19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2018-214598","article-title":"Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102454_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2018.09.001","article-title":"Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase","volume":"143","author":"Mertz","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2020.102454_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.jaut.2020.102454_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1869-5760-3-43","article-title":"Drug-induced uveitis","volume":"3","author":"London","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.jaut.2020.102454_bib23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00198-014-2872-5","article-title":"Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial","volume":"26","author":"Patel","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jaut.2020.102454_bib24","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaut.2020.102454_bib25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0161-6420(97)30278-4","article-title":"Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention","volume":"104","author":"Chavez-de la Paz","year":"1997","journal-title":"Ophthalmology"},{"issue":"Pt 3a","key":"10.1016\/j.jaut.2020.102454_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/eye.1999.89","article-title":"Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS","volume":"13","author":"Bainbridge","year":"1999","journal-title":"Eye"},{"key":"10.1016\/j.jaut.2020.102454_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/clinids\/24.3.529","article-title":"Uveitis following administration of the protease inhibitor indinavir to a patient with AIDS","volume":"24","author":"Gariano","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jaut.2020.102454_bib28","first-page":"57","article-title":"Toxic uveitis caused by pharmacodynamic interactions of Rifabutin and protease inhibitors: a case report","author":"Ebraert","year":"2007","journal-title":"Bull. Soc. Belge Ophtalmol."},{"key":"10.1016\/j.jaut.2020.102454_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tjo.2014.08.004","article-title":"Bilateral uveitis associated with concurrent administration of rifabutin and nelfinavir","volume":"5","author":"Cheng","year":"2015","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.jaut.2020.102454_bib30","doi-asserted-by":"crossref","first-page":"E431","DOI":"10.1503\/cmaj.111752","article-title":"Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study","volume":"184","author":"Etminan","year":"2012","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.jaut.2020.102454_bib31","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2006-2023H","article-title":"Bisphosphonates: mode of action and pharmacology","volume":"119","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaut.2020.102454_bib32","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.5301\/ejo.5000724","article-title":"A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab","volume":"26","author":"Abu Samra","year":"2016","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.jaut.2020.102454_bib33","doi-asserted-by":"crossref","DOI":"10.21767\/2471-8041.100044","article-title":"Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma","volume":"3","author":"Baughman","year":"2017","journal-title":"Med. Case Rep."},{"key":"10.1016\/j.jaut.2020.102454_bib34","doi-asserted-by":"crossref","first-page":"100761","DOI":"10.1016\/j.preteyeres.2019.05.002","article-title":"Neoplasia and intraocular inflammation: from masquerade syndromes to immunotherapy-induced uveitis","volume":"72","author":"Touhami","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jaut.2020.102454_bib35","first-page":"140","article-title":"Ipilimumab-induced ocular and orbital inflammation--A case series and review of the literature","volume":"24","author":"Papavasileiou","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.jaut.2020.102454_bib36","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2015.05.020","article-title":"Impact of ocular chronic graft-versus-host disease on quality of life","volume":"21","author":"Sun","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.jaut.2020.102454_bib37","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/ICO.0b013e3181ca321c","article-title":"Ocular graft-versus-host disease after allogeneic stem cell transplantation","volume":"29","author":"Westeneng","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jaut.2020.102454_bib38","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102454_bib39","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102454_bib40","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","article-title":"Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature","volume":"131","author":"Read","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.jaut.2020.102454_bib41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CJI.0000000000000066","article-title":"Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma","volume":"38","author":"Crosson","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/j.jaut.2020.102454_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0000000000000154","article-title":"Vogt-Koyanagi-Harada\u2013like syndrome complicating pembrolizumab treatment for metastatic melanoma","volume":"40","author":"Bricout","year":"2017","journal-title":"J. Immunother."},{"key":"10.1016\/j.jaut.2020.102454_bib43","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/CMR.0000000000000505","article-title":"Incomplete Vogt\u2013Koyanagi\u2013Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma","volume":"28","author":"Diamantopoulos","year":"2018","journal-title":"Melanoma Res."},{"key":"10.1016\/j.jaut.2020.102454_bib44","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/1346-8138.14273","article-title":"HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy","volume":"45","author":"Fujimura","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jaut.2020.102454_bib45","first-page":"67","article-title":"Vogt-koyanagi-harada disease-like uveitis during nivolumab (Anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma","volume":"10","author":"Obata","year":"2019","journal-title":"COPE"},{"key":"10.1016\/j.jaut.2020.102454_bib46","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ccr3.911","article-title":"Vogt\u2010Koyanagi\u2010Harada disease\u2010like posterior uveitis in the course of nivolumab (anti\u2010PD\u20101 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma","volume":"5","author":"Matsuo","year":"2017","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jaut.2020.102454_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.14200","article-title":"Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma","volume":"45","author":"Fusumae","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jaut.2020.102454_bib48","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/intimm\/8.5.799","article-title":"Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease","volume":"8","author":"Sugita","year":"1996","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jaut.2020.102454_bib49","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1167\/iovs.05-1547","article-title":"Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens","volume":"47","author":"Sugita","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jaut.2020.102454_bib50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1167\/iovs.08-2397","article-title":"PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation","volume":"50","author":"Yang","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jaut.2020.102454_bib51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1167\/iovs.08-2536","article-title":"Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism","volume":"50","author":"Sugita","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089684112030069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089684112030069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:26:19Z","timestamp":1760257579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089684112030069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":51,"alternative-id":["S089684112030069X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102454","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102454"}}